; and (2) by adding at the end the following new paragraph: (4) Application of pharmacy performance measures (A) Evaluation of pharmacy performance measures Not later than 6 months after the date of enactment of this Act, and annually thereafter, the Secretary shall complete an evaluation of the performance measures used by PDP sponsors offering prescription drug plans and MA organizations offering MA–PD plans to assess pharmacy price concessions or any other fees based on performance, as established in network pharmacy agreements. Each such evaluation shall (to the extent practicable) include at least 5 years of retrospective information to examine the following: (i) How measures are being applied to pharmacies, including whether such measures are applied based on the type of pharmacy (including specialty pharmacy), drugs dispensed, and pharmacy services used to dispense and manage drugs. (ii) Whether, with respect to each such measure, such measure results in anything of value including any fees, pharmacy price concessions, discounts, or incentives, transferred to or received from a pharmacy by a PDP sponsor offering a prescription drug plan or MA organization offering an MA–PD plan after the point-of-sale of a drug, broken down by type of pharmacy and the drug dispensed. (iii) The extent to which each measure is applied across prescription drug plans offered by a PDP sponsor and MA–PD plans offered by an MA organization and if such application is uniform. (iv) How measures are applied and if they are uniformly applied to all in-network types of pharmacies or only certain pharmacies within a network. (v) How and when pharmacies are provided notice of measures, as well as methods and actual data calculations used to evaluate performance, and evaluation outcomes by type of pharmacy. (vi) How pharmacy performance is evaluated using such measures and the extent to which the goals or targets are— (I) achievable at scale; (II) structured to improve patient outcomes